Market research
MEIP MEI Pharma Inc
NASDAQ USD Healthcare
Latest close
As of 25 Sep 2025
Test a moving-average rule with historical data.
Market facts
- Market cap
- 101M
- P/E ratio
- Not available
- Analyst target
- 20
- Dividend yield
- Not available
- Beta
- 0.22
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 101M
- P/E ratio
- Not available
- Analyst target
- 20
- Dividend yield
- Not available
- Beta
- 0.22
About
About MEI Pharma Inc
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
Research context
MEI Pharma Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the MEIP discussion.
5 years, 7 months ago
MEI Pharma, Inc is currently in a long term downtrend where the price is trading 9.7% below its 200 day moving average.
From a valuation standpoint, the stock is 99.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 10.1.
MEI Pharma, Inc's total revenue rose by 809.4% to $9M since the same quarter in the previous year.
Its net income has increased by 43.3% to $-11M since the same quarter in the previous year.
Finally, its free cash flow grew by 45.1% to $-6M since the same quarter in the previous year.
Based on the above factors, MEI Pharma, Inc gets an overall score of 4/5.